Aurinia Q3 revenue $73.5M (+8%), net income $31.6M; LUPKYNIS sales up 27% YoY, FY guidance raised

Aurinia Pharmaceuticals Inc.

2025-Q3 EPS reported $0.55 vs consensus $0.16 ▲ beat (+237.0%)

Q3 2025 net product sales of LUPKYNIS $70.6M, up 27% YoY; 9-month $197.2M, up 24%.
Diluted EPS $0.23 (Q3), up 130% YoY; net income $31.6M, up 119%.
FY 2025 net product sales guidance raised to $265-270M from $250-260M; total revenue guidance raised to $275-280M.
Cash from operating activities $44.5M in Q3, up 162% YoY; cash position $351.8M.
Positive Phase 1 results for aritinercept (BAFF/APRIL inhibitor); clinical studies in two autoimmune diseases planned by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.